The 6MWT provides a simple objective measure of functional exercise capacity [1] , and is widely used as a marker of disease severity and response to therapy. We report here the change in functional exercise capacity, as measured by the 6MWT, in patients with AL amyloidosis who have undergone chemotherapy. Patients and methods: As part of our prospective observational study of chemotherapy in AL amyloidosis (ALchemy), we conducted 6MWT at diagnosis (baseline) and at 12 (range 9 -15) month follow-up, after patients had received chemotherapy. The 6MWT was conducted according to ATS guidelines [1] . Response to chemotherapy was assessed using the dFLC method [2] . Statistical analysis was performed using IBM SPSS 22. Results: 402 patients performed a 6MWT at their baseline (diagnostic) visit. Of these, 203 had a 6MWT at 12 (range 9 -15) months. At baseline, the 6MWT distance, expressed as the percentage of age-corrected expected walking distance, correlated with many other established markers of disease (Table 1) . Patients who achieved a complete response (CR) or very good partial response (VGPR) to chemotherapy by 12 months showed improved or stable 6MWT distance at 12 months, compared with those who had achieved only a partial response (PR) or no response (NR) to chemotherapy, whose walk distances were largely worse at 12 months (Figure 1 ). Baseline 6MWT distance was shown to be predictive of outcome in a Kaplan-Meier analysis: Median survival for those who walked < 50% of their expected distance was 5 months (n = 86) and 38 months for those who walked 50 -89% of their expected distance (n = 184). Median survival was not reached for those who walked > 90% of their expected distance (n=x). Discussion and conclusions: The 6MWT at baseline provides a useful objective measure of patient functional capacity in AL amyloidosis and predicts survival. Achieving a CR or VGPR with chemotherapy typically results in improvement in functional capacity, in marked contrast to lesser degrees of clonal response. Further studies are planned.
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